#USA #New York #Microtech #Medinol #pressure microsensor

Microtech Introduces Groundbreaking Atrial Microsensor Implants

On June 9, 2025, Microtech, a fully-owned subsidiary of Medinol, proudly announced a significant milestone: the first-ever implantations of its atrial-pressure microsensors in the United States. These innovative devices were surgically implanted on May 16, 2025, by Dr. Koji Takeda, the Director of Adult Cardiac Transplant Surgery at New York-Presbyterian/Columbia University Irving Medical Center.

The atrial microsensor is uniquely designed, showcasing a remarkably small size and a fully passive structure, devoid of any electronic components or antennas. This allows the device to receive and transmit data using ultrasound technology. As a result, Microtech’s microsensors can operate independently or seamlessly integrate with existing implants, evolving them into intelligent devices capable of simultaneous diagnostics and therapy.

In this initial phase, two microsensors were implanted in patients who received left ventricular assist devices (LVADs) in New York. This achievement builds on the earlier success of five similar microsensors successfully implanted under comparable conditions in Israel. Dr. Takeda remarked on the efficiency of the procedure, noting that the implantation took only about five minutes with minimal modifications to the existing LVAD implantation techniques.

Dr. Nir Uriel, the Director of Advanced Heart Failure and Cardiac Transplantation at NewYork-Presbyterian and the lead investigator for the Microtech First-In-Human (FIH) study, expressed optimism regarding the capabilities of the new device. He emphasized how the non-invasive monitoring of left and right cardiac pressures would significantly enhance patient care, shifting the approach from symptom-based to parametric therapy. This transition marks a critical advance in the management of heart failure patients, allowing for more precise and personalized treatment plans.

Dr. Uriel has noted, “To date, we have been able to measure these pressures easily, reliably, and repetitively in all patients participating in the study,” highlighting the device's promise in clinical settings. He also holds a position as an associate professor of medicine in the Greenberg Division of Cardiology at Weill Cornell Medicine and as a professor of cardiology at the Vagelos College of Physicians and Surgeons at Columbia University, underlining his extensive expertise in the field.

The Microtech FIH study is set to enroll approximately 15 patients across Israel and the U.S., paving the way for broader clinical applications. Dr. Yoram Richter, the CEO of Medinol, expressed enthusiasm about the advances made in the study, as well as the performance of the microsensors up to this point. He stated, “We are thrilled with the study’s progress and sensor performance thus far, and we anticipate that this will enable us to demonstrate the viability, usability, and accuracy of this system.” Dr. Richter also mentioned ongoing efforts to integrate microsensors into existing medical devices, showcasing the true potential of this transformative technology.

The Vision of Medinol

Medinol is committed to redefining the paradigms in diagnosing and treating medical conditions. The company is focused on designing cutting-edge devices for several areas of medical application, which include stent implantations, minimizing complications during structural cardiac procedures, and providing real-time insights into physiological metrics through implantable sensors. Medinol is boldly rethinking current technologies and practices, with an unwavering focus on pioneer new devices that expand physician capabilities both physically and geographically. Collaborating closely with medical professionals and industry partners, Medinol is actively shaping the future of healthcare.

For more information regarding these advancements, visit www.medinol.com or reach out to Jeff Roach, the Director of Commercial Operations at [email protected].